Results 131 to 140 of about 23,822 (250)

Pyloric Pseudonecrosis Caused by Biliary Peritonitis: A Rare Intraoperative Pitfall

open access: yesClinical Case Reports, Volume 14, Issue 10, October 2026.
ABSTRACT Biliary peritonitis can cause subserosal bile staining that mimics pyloric or duodenal necrosis. When endoscopy or ICG fluorescence is unavailable, pseudonecrosis remains an operative diagnosis of exclusion, supported by preserved serosal integrity, absence of visible perforation, careful inspection, and uneventful 1‐month follow‐up.
Christian Mouawad   +2 more
wiley   +1 more source

When Current Severity Overrides Reassuring Findings: TG18‐Guided Biliary Drainage in ERCP‐Confirmed Purulent Cholangitis

open access: yesClinical Case Reports, Volume 14, Issue 10, October 2026.
ABSTRACT A 42‐year‐old antibiotic‐naïve man with previous laparoscopic cholecystectomy and poorly controlled type 2 diabetes mellitus (HbA1c 9.7%) presented with Charcot's triad 7 days after a formally documented normal hepatobiliary evaluation (alanine aminotransferase [ALT] 22 U/L; total bilirubin 0.7 mg/dL [12 μmol/L]; common bile duct [CBD] ≤ 5 mm ...
Hatem Mousa Taha, Khaled Hatem Taha
wiley   +1 more source

Mapping Mutations and Signaling Network Interactions to Guide Precision Therapy in Gallbladder Cancer

open access: yesCancer Reports, Volume 9, Issue 10, October 2026.
ABSTRACT Background Gallbladder cancer (GBC) is a biologically complex malignancy arising from the epithelial lining of the gallbladder, with adenocarcinoma constituting the major histological subtype. Early detection is challenging because of vague clinical manifestations and the organ's deep‐seated anatomical location, resulting in diagnosis at ...
Nisha Manav   +4 more
wiley   +1 more source

Patient and Caregiver Reported Barriers to Cancer Clinical Trial Participation: A Scoping Review

open access: yesCancer Reports, Volume 9, Issue 10, October 2026.
ABSTRACT Background The development of cancer treatments relies on patient participation in clinical trials, yet poor recruitment and retention hinder evidence generation. There exists an urgent need for trial designs that address patient‐identified barriers, informational gaps, and concerns. The goal of this evidence synthesis was to identify patient‐
Sarah Scruton   +17 more
wiley   +1 more source

Expression of COL6A1 in Tumor Matrix of Cholangiocarcinoma and Its Mechanism of Tumor Progression

open access: yesCancer Reports, Volume 9, Issue 10, October 2026.
ABSTRACT Background Cholangiocarcinoma (CCA), a malignant tumor originating from the bile duct epithelial cells, is characterized by aggressive invasion and poor prognosis. Abnormal remodeling of the tumor microenvironment plays a pivotal role in its disease progression.
Weibin Zhang   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy